Our Company is the result of more than 20 years of research in aging by scientists in Europe, The United States of America and Asia

Our Project

20 years of research in aging by scientists in Europe, The United States of America and Asia

Our Philosophy

We reinvest 100% of the profits from sales of our skincare treatments in R&D in rare diseases in children

New Technologies

Give yourself the best everyday skincare treatment possible – give yourself Insolitus with Cap® Peptides

Advanced Medical Projects


Advanced Medical Projects is a biotechnology company with presence in Madrid and Boston, interested in rare diseases caused by DNA stability, oxidative stress and low telomerase activity, also in syndromes caused by accelerated aging where the previous factors are proven to be very important. Most of these diseases are pediatric, like dyskeratosis congenita or ataxia telangiectasia, but some are present in adults, like idiopathic pulmonary fibrosis. We follow a “bottom-up” approach to research, so we study many different aspects of aging, telomerase function and chromosome stability to understand basic biological and physiological areas. Once we understand basic principles, we look for mechanisms able to act over some particular biochemical and genetic pathway.
AMP is the first company to develop a patented family of human peptides as a therapeutic product candidate able to increase Telomerase activity in senescent cells, increase DNA repair and also increase cell response against oxidative stress. Most of the drugs are developed as PLGA encapsulated principles to be administered as i.v. once or twice per month. Telomerase is a molecular complex of very difficult biomedical manipulation; its role is to maintain the length of telomeres, which are special DNA sequences located at the end of chromosomes to protect them from degradation.
Working on oxidative stress, we have developed a new drug against Fragile X Syndrome, that already passed Clinical Phase III. Patients treated with the drug, versus those treated with the placebo, have shown very clear improvement in cognitive and learning capacities and functions. We plan to bring this drug to patients by the end of 2016.
As cells divide in normal life, telomeres become shorter and shorter, and eventually the cell becomes senescent, does not repair its DNA and suffers more and more from oxidative stress. Abnormal telomere shortening means abnormal aging and also increase of mutations that may cause cancer. On the other hand, oxidative stress is a key factor in fibrosis processes.
Our patented GSE24-2 peptides have already demonstrated in vitro potential in several diseases, including cancer, Dyskeratosis Congenita, Werner Syndrome, Idiopathic Pulmonary Fibrosis, etc. GSE24-2 is currently in preclinical studies, in animal models, and based on the results generated so far we hope to reach very soon studies in human patients. Currently, we are also developing new administration platforms for these peptides, able to guarantee safety and correct dosage.
Finally, the company has also developed a complete line of cosmetics products using some of its patented molecules. These products are marketed worldwide and we reinvest 100% of all profits in the development of these pediatric drugs.

Experience (Years)


Reinvest all profits in the development of these pediatric drugs.






Dr. Molina is an entrepreneur in the biotechnology field since 1998. He has created more than 8 companies in the USA and Europe. He has over 17 years of experience in the pharma industry as Director of Discovery, Technical Director and CEO of different companies in the USA, France and Spain, working in cancer, pulmonary, immune and neurological diseases, setting up screening system to develop new drugs based on both short peptides and small molecules. Dr. Molina studied molecular & cell biology at University of Seville, Columbia University, NYU & Georgetown, he obtained his MBA at IESE and HBS. He is married, one daughter and his passions are gliders, Cuban cigars, wine, Real Madrid soccer team and above all fighting rare diseases.




A born New Yorker and die-hard New York Mets fan, she studied Psychology and Art History at State University of New York, with different post grade courses in France and Spain and is currently working on a Masters in Marketing. Amber has over 15 years of experience in the pharma industry always focused in regulatory aspects, compliance and relationship with EMA and FDA. During her career at AMP Pharmaceuticals she has assisted in the development of drugs to fight against different diseases focusing on Fragile X and Down Syndrome. She is also now heading a European project developing a new diagnostic system for neurodegenerative diseases such as Parkinsons and Alzheimers. Amber is passionate about horses and runs a facility just outside of Madrid specializing in  equine therapy for children and adults with handicaps – from Autism to Scoliosis and social issues. Amber is a painter and a passionate chef with extensive  experience in French and Spanish cuisine, She is married with one daughter, one horse, five dogs, five cats, eight fish and one hedgehog (so far).


  • Edificio Nuevas Empresas
  • C/ Buendia 11, Sala 58
  • 19005 Guadalajara, SPAIN